UNSPSC 51112001: Capecitabine

This classification denotes a pyrimidine antagonist with the molecular formula C15H22FN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6804DJ8Z9U, chemically known as pentyl 1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate but generally known as capecitabine, which bears US NIH Compound Identifier 60953. European Medicines Agency schedules Capecitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12474MIG.

UNSPSC 51112001 Capecitabine, a Commodity code, encompasses the supply of generic pharmaceutical products to state and local government healthcare facilities, including hospitals, correctional institutions, and public health departments. Recent solicitations under this code focus on establishing multi-source supplier agreements for branded and generic pharmaceuticals distributed through authorized pharmaceutical wholesalers to participating state and local entities. State and local governments procure under this code primarily through cooperative purchasing vehicles managed by state procurement offices, such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which aggregate demand across multiple jurisdictions and member states to achieve volume-based pricing and supply chain efficiency. The issuing bodies span state departments of health and administration, county health departments, municipal hospital systems, and state-operated correctional facilities. Vendors must maintain FDA compliance, current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, contractual relationships with authorized pharmaceutical wholesalers, and comprehensive insurance coverage including $5,000,000 in commercial general liability per occurrence.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 for generic multi-source pharmaceuticals and over-the-counter products, with proposals due March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with all products available in the marketplace by May 15, 2026 and resulting contracts effective July 1, 2026. Evaluation criteria weight price competitiveness at 75 percent, fixed pricing at 10 percent, compliance with administrative fee data format requirements at 5 percent, EDI capability at 5 percent, and agreement to a 3 percent administrative fee at 5 percent. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs. The contract term is two years for new responders with optional extensions, while incumbent responders' amendments align with existing agreement expiration dates through June 30, 2028. Vendors should anticipate performance penalties ranging from $200 to $1,500 per violation for issues such as late reporting or missed onboarding timelines.